[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"American University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100620652","dietary-intervention-for-migraine-relief-100620652",false,"NCT07360405","Dietary Intervention for Migraine Relief","Diet-Based Treatment for Migraine Relief","Inclusion Criteria:\n\n* Men and women of all races and ethnicities\n* Age 18-75 years\n* Documented diagnosis of chronic or episodic migraine for at least 6 months, based on International Classification of Headache Disorders, 3rd edition (ICHD-III) criteria, defined as:\n\n  * 8 headache days per month, and\n  * 4 migraine days per month\n* Migraine onset before age 50\n* On a stable medication regimen for at least 1 month prior to enrollment\n* Willing to maintain stable medications throughout the study\n* Willing to discontinue supplements during the study period\n* Women of childbearing potential must be willing to use birth control during the study timeframe\n\nExclusion Criteria:\n\n* Current pregnancy, plans to become pregnant during the study timeframe, or current breastfeeding\n* Current use of medications affecting glutamatergic or gamma-Aminobutyric Acid (GABA) neurotransmission (unless discontinued under physician guidance)\n* Current use of quarterly injectable migraine preventive medications\n* Unwillingness to modify dietary intake or to stop alcohol and marijuana use during the study\n* Substance use disorder within the past year\n* Diagnosed seizure disorder\n* Severe asthma requiring past hospitalization","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress.\n\nThe main questions this study aims to answer are:\n\nDoes following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life?\n\nAre improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity?\n\nResearchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures.\n\nParticipants will:\n\nComplete a baseline run-in period while tracking headaches using a daily migraine diary\n\nEither follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control\n\nComplete standardized questionnaires related to migraine symptoms and quality of life\n\nProvide blood samples for laboratory analyses\n\nUndergo neuroimaging assessments (for a subset of participants)",[27],"Migraine",[27,29,30,31],"Chronic pain","Diet","Glutamate","NOT_YET_RECRUITING","2026-01-16",{"date":35,"type":36},"2026-01-22","ACTUAL",{"date":38,"type":21},"2026-01",{"date":40,"type":21},"2027-03",{"name":42,"class":43},"American University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100469710","cerebellum-and-autism-regional-specialization-for-social-and-executive-functions-100469710","NCT05396352","Cerebellum and Autism: Regional Specialization for Social and Executive Functions","Please note: This study takes place at American University and Georgetown University in Washington, DC. We do not have funds for travel and lodging available for this study, so participants should be local to the DC region.\n\nInclusion Criteria:\n\nAll participants\n\n* Aged 18-35\n* Able to provide written, informed consent\n* NIH Toolbox age-adjusted Cognitive Function Composite standard score ≥ 85\n* Native English speaker\n* Right-handed\n* Not pregnant\n* Able to attend all study sessions\n* Pass safety screening for MRI and neuromodulation (e.g. no metal in body, implanted devices, history of seizure, claustrophobia)\n\nAdditional INCLUSION criteria for adults with autism Either\n\n* Prior research-reliable diagnosis of autism spectrum disorder (ASD) Or\n* Meet DSM-5 criteria for ASD confirmed with ADOS-2 via research-reliable clinical assessment\n\nExclusion Criteria:\n\nNeurotypical adults\n\n* Age \\\u003C18 or \\>35\n* NIH Toolbox age-adjusted Cognitive Function Composite standard score \\\u003C 85\n* Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia)\n* Current or prior history of neurological or neurodevelopmental condition or brain injury\n* Psychotropic medication\n* Pregnancy\n\nAdults with autism\n\n* Age \\\u003C18 or \\>35\n* Participants with a legal authorized representative\n* NIH Toolbox age-adjusted Cognitive Function Composite standard score \\\u003C 85\n* Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia)\n* Pregnancy",true,"35 Years",{"count":54,"type":21},80,[24],"The goal of this study is to determine the impact of neuromodulation to the cerebellum on social and executive functions in neurotypical young adults and young adults with autism.",[58,59],"Autism","Autism Spectrum Disorder","RECRUITING","2025-09-29",{"date":63,"type":36},"2025-10-02",{"date":65,"type":36},"2022-01-01",{"date":67,"type":21},"2025-12-31",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":5},"100491188","phase-3-confirmation-of-diet-as-a-treatment-for-gulf-war-illness-100491188","NCT05675878","Confirmation of Diet as a Treatment for Gulf War Illness","Inclusion Criteria:\n\n* Males and Females of all races and ethnicities who are ≤75 yrs of age\n* Served in the 1990-1991 Persian Gulf War\n* Fulfill both Center for Disease Control (CDC) and Kansas definitions of Gulf War Illness\n* Stable medication regimen for ≥1 month and willing to keep medications and supplements stable throughout study participation\n\nExclusion Criteria:\n\n* Recent substance use disorder (past year)\n* Unwilling to stop using alcohol, tobacco (including vaping) and\u002For marijuana; or unwilling to change diet\n* Diagnosed seizure disorder or severe asthma requiring past hospitalization\n* Currently taking medication which affects glutamatergic or GABAergic neurotransmission (but can work with their physician to wean off of these medications prior to participating)","50 Years",{"count":77,"type":21},160,[79],"PHASE3","This clinical trial aims to confirm previous findings from a smaller study which demonstrated significant improvements in all symptoms among veterans with Gulf War Illness after one month on the dietary intervention. The main objectives of this study are: 1) to confirm previous findings of treatment response to the diet in a larger and more diverse group; 2) to examine how changes in the nervous system may be the reason for improvement; and 3) to identify markers which change in the blood after one month on the diet. Participants will have baseline measures collected and then will be randomized into the intervention or wait-listed control group, which they will follow for one month before being reassessed.",[82,83],"Gulf War Syndrome","Gulf War Illness",[83,85,82,30,86],"GWI","Treatment","2024-07-05",{"date":89,"type":36},"2024-07-09",{"date":91,"type":36},"2023-03-01",{"date":93,"type":21},"2025-12-30",{"name":42,"class":43},""]